Recently, anti-IL-5 therapies, such as anti-IL-5 and anti-IL-5 receptor antibodies, have demonstrated efficacy in managing chronic HES by reducing eosinophil counts and steroid-sparing benefits [6]. Here, IL5 is linked to hypereosinophilic syndrome.